Vimarsana
Biggest News Aggregation in the World

Bryn Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bryn Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bryn Pharma Today - Breaking & Trending Today

New Administration Routes for Adrenaline in Anaphylaxis - Vimarsana News

New Administration Routes for Adrenaline in Anaphylaxis

Emerging formulations are intended to facilitate the use of adrenaline and reduce delays in administration.

Positive Results from Pivotal Study for Bryn Pharma's Investigational Epinephrine Nasal Spray Published in the Journal of Allergy and Clinical Immunology: Global - Vimarsana News

Positive Results from Pivotal Study for Bryn Pharma's Investigational Epinephrine Nasal Spray Published in the Journal of Allergy and Clinical Immunology: Global

~ First study to demonstrate rapid and sustained absorption of NDS1C epinephrine nasal spray compared to epinephrine intramuscular autoinjector, while offering higher and more sustained therapeutic plasma levels ~ ~ Study also found that NDS1C was...

Around the house: All Africa Capital hires first GC, Buffalo Bills end hunt for new legal chief - Vimarsana News

Around the house: All Africa Capital hires first GC, Buffalo Bills end hunt for new legal chief

Around the house: All Africa Capital hires first GC, Buffalo Bills end hunt for new legal chief

FDA rejects neffy epinephrine nasal spray for severe allergic reactions pending further trial data - Vimarsana News

FDA rejects neffy epinephrine nasal spray for severe allergic reactions pending further trial data

ASR Pharma said it was surprised and "deeply disappointed" by the FDA request for more trial data on its neffy nasal spray for severe allergic reactions.

Mallinckrodt Bankruptcy Reveals $21 Million Paid to Big Law Trio - Vimarsana News

Mallinckrodt Bankruptcy Reveals $21 Million Paid to Big Law Trio

Mallinckrodt PLC, a specialty pharmaceutical manufacturer that has filed for bankruptcy twice in the past three years, paid more than $21.7 million to three law firms ahead of its second insolvency filing last month.